AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 159 filers reported holding AKERO THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $265,136 | +213.9% | 5,242 | +189.8% | 0.00% | – |
| Q2 2023 | $84,460 | +52.2% | 1,809 | +24.8% | 0.00% | – |
| Q1 2023 | $55,477 | -10.5% | 1,450 | +27.8% | 0.00% | – |
| Q4 2022 | $62,000 | +29.2% | 1,135 | -20.3% | 0.00% | – |
| Q3 2022 | $48,000 | +1500.0% | 1,424 | +419.7% | 0.00% | – |
| Q2 2022 | $3,000 | -25.0% | 274 | 0.0% | 0.00% | – |
| Q1 2022 | $4,000 | -81.8% | 274 | -72.5% | 0.00% | – |
| Q4 2021 | $22,000 | +15.8% | 997 | +12.7% | 0.00% | – |
| Q3 2021 | $19,000 | -13.6% | 885 | 0.0% | 0.00% | – |
| Q2 2021 | $22,000 | -40.5% | 885 | -31.1% | 0.00% | – |
| Q1 2021 | $37,000 | – | 1,285 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |